Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study

Targeting specific molecular alterations in glioblastoma (GBM) might more effectively kill tumor cells and increase survival. Vandetanib inhibits epidermal growth factor receptor and vascular endothelial growth factor receptor 2. Sirolimus inhibits mammalian target of rapamycin (mTOR), a member the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Neurooncol
Main Authors: Chheda, Milan G., Wen, Patrick Y., Hochberg, Fred H., Chi, Andrew S., Drappatz, Jan, Eichler, April F., Yang, Daniel, Beroukhim, Rameen, Norden, Andrew D., Gerstner, Elizabeth R., Betensky, Rebecca A., Batchelor, Tracy T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4324090/
https://ncbi.nlm.nih.gov/pubmed/25503302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-014-1680-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados